Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | POLB | P06746 | 5/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074380 | 0.90 | MAPT (0.75) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1072405 | 0.90 | MAPT (0.79) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1549542 | 0.90 | MAPT (0.75) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1075252 | 0.88 | MAPT (0.79) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1074351 | 0.87 | MAPT (0.79) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1071099 | 0.85 | MAPT (0.71) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1074275 | 0.83 | MAPT (0.80) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL15410479 | 0.81 | MAPT (0.88) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1074794 | 0.81 | MAPT (0.84) | RXFP1TP53MAPTPOLBBLM | |
| SCHEMBL1071949 | 0.81 | MAPT (0.80) | RXFP1TP53MAPTPOLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | NOX4, NOX1, CYBB | RXFP1 364/4885TP53 2443/4885MAPT 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.